Sugi Predict

Sugi Predict / Targets / IDH2

IDH2

Isocitrate dehydrogenase [NADP], mitochondrial · P48735 · IDH2 on Sugi Atlas →

26,892 patent compounds predicted against IDH2, 13,533 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1391541 SCHEMBL1391541 0.58 16/20
SCHEMBL1391872 SCHEMBL1391872 0.57 14/20
SCHEMBL1391746 SCHEMBL1391746 0.55 14/20
SCHEMBL1298643 SCHEMBL1298643 0.63 13/20
SCHEMBL1298646 SCHEMBL1298646 0.63 13/20
SCHEMBL1299016 SCHEMBL1299016 0.63 13/20
SCHEMBL1298871 SCHEMBL1298871 0.61 13/20
SCHEMBL1298471 SCHEMBL1298471 0.60 13/20
SCHEMBL1299513 SCHEMBL1299513 0.60 13/20
SCHEMBL1391748 SCHEMBL1391748 0.60 13/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1391553) 0.58 13/20
SCHEMBL1391747 SCHEMBL1391747 0.58 13/20
SCHEMBL1391708 SCHEMBL1391708 0.58 13/20
SCHEMBL1391883 SCHEMBL1391883 0.56 13/20
SCHEMBL1391778 SCHEMBL1391778 0.54 13/20
SCHEMBL1391539 SCHEMBL1391539 0.52 13/20
SCHEMBL1391540 SCHEMBL1391540 0.81 12/20
SCHEMBL1391661 SCHEMBL1391661 0.74 12/20
SCHEMBL1391823 SCHEMBL1391823 0.74 12/20
SCHEMBL1298107 SCHEMBL1298107 0.63 12/20

Clinical trials — most relevant to IDH2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia PHASE3RECRUITING
Glutamate for Metabolic Intervention in Coronary Surgery PHASE3COMPLETED
An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation PHASE3COMPLETED
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype PHASE2ACTIVE_NOT_RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
Phase 2 Study of IDH305 in Low Grade Gliomas PHASE2WITHDRAWN
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy PHASE2SUSPENDED
Acetylcarnitine and Insulin Sensitivity PHASE2COMPLETED
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation PHASE2UNKNOWN
Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation PHASE2WITHDRAWN
Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy PHASE2ACTIVE_NOT_RECRUITING
NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline PHASE2RECRUITING
A Clinical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia PHASE2RECRUITING
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study) PHASE2RECRUITING
IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation PHASE1COMPLETED
Food Effect Study of AG-221 in Healthy Male Subjects PHASE1COMPLETED
Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted Therapy nanUNKNOWN
Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma nanNOT_YET_RECRUITING
Surgical Management of Low Grade Glioma nanNOT_YET_RECRUITING
Construction and Application of an IDH Mutation-Targeted PET/MRI Imaging Framework for Precision Diagnosis of Gliomas nanRECRUITING
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia nanUNKNOWN
Clinical Development of Cancer-Specific MRS Biomarkers in Malignant Gliomas nanCOMPLETED
Predictive Role of New Biomarkers for Hypersensitive Patients to Radiation in Breast Cancer (BIORISE) nanACTIVE_NOT_RECRUITING
IDH1/IDH2 Mutation Frequency in Acute Myeloblastic Patients nanUNKNOWN
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside nanUNKNOWN
Detection of IDH2 Mutations and Monitoring Molecular Residual Disease in Patients With AML nanCOMPLETED
ALDH2 Single Nucleotide Polymorphisms and Prognosis of Esophageal Cancer Patients nanRECRUITING
Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia nanCOMPLETED
Nicotinamide Levels in Serum, Aqueous Humor, and Tear Film in Glaucoma and Correlations With Mitochondrial Damage-Associated Molecular Patterns (mtDAMPs) and Senescence-Associated Secretory Phenotype (SASP) nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a IDH2 binder may also engage these)

ProteinNameSimilarity
Q4R502 — 1.000 Q4R502 →
Q04467 — 1.000 Q04467 →
P54071 — 1.000 P54071 →
P56574 — 1.000 P56574 →
P33198 — 1.000 P33198 →
Q5R9C5 — 1.000 Q5R9C5 →
Q6XUZ5 — 1.000 Q6XUZ5 →
O13285 — 1.000 O13285 →
B7G620 — 1.000 B7G620 →
O14254 — 1.000 O14254 →
Q9SLK0 — 1.000 Q9SLK0 →
P21954 — 1.000 P21954 →
P9WKL1 — 1.000 P9WKL1 →
P41939 — 1.000 P41939 →
Q75JR3 — 0.999 Q75JR3 →
Q8LPJ5 — 0.999 Q8LPJ5 →
P50217 — 0.999 P50217 →
Q9Z2K9 — 0.999 Q9Z2K9 →
O13294 — 0.998 O13294 →
P79089 — 0.998 P79089 →
Q40345 — 0.997 Q40345 →
O88844 — 0.997 O88844 →
Q9MTP9 — 0.997 Q9MTP9 →
Q9XSG3 — 0.997 Q9XSG3 →
Q01874 — 0.997 Q01874 →
P50215 — 0.996 P50215 →
P61293 — 0.996 P61293 →
Q9Z2K8 — 0.996 Q9Z2K8 →
Q9SRZ6 — 0.996 Q9SRZ6 →
Q01873 — 0.996 Q01873 →